Irritation and Anal Bleeding in Patients Affected by Hemorrhoids: Comparative Evaluation of Three Different Treatments.
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 105
- 试验地点
- 1
- 主要终点
- delta of time necessary for the disappearance of bleeding
研究概览
简要总结
Haemorrhoidal disease is an increasingly frequent benign condition, able to negatively affect the quality of working and relationship life in affected individuals.The primary objective of the study is the comparative assessment of the time necessary for the disappearance of bleeding comparatively in the three different therapies (controls, ProtFlav and ProtCent) to identify, if any, the most effective treatment, in terms of time reduction for the disappearance of bleeding in subjects affected by haemorrhoidal disease.
Patients enrolled will be randomized into 3 groups:
- the control group in which the patients will be subjected to the standard therapeutic care (diet rich in water and vegetable fibers, hygienic),
- interventional group "ProtFlav": in which oral supplements (flavonoid-based supplements - ProtFlav) will be added to standard of care
- interventional group "ProtCent": in which an anal application of a Centella based cream (Centella asiatica - ProtCent) will be added to standard of care
详细描述
Haemorrhoidal disease is an increasingly frequent benign condition, able to negatively affect the quality of working and relationship life in affected individuals.The primary objective of the study is the comparative assessment of the time necessary for the disappearance of bleeding comparatively in the three different therapies (controls, ProtFlav and ProtCent) to identify, if any, the most effective treatment, in terms of time reduction for the disappearance of bleeding in subjects affected by haemorrhoidal disease.
Secondary objectives are the evaluation of the longitudinal trend in time of anal irritation measured with the VAS scale and the study of the longitudinal performance of BMI (Body Mass Index).
The patients enrolled in the protocol will be randomized into 3 groups: the control group in which the patients will be subjected to a diet rich in water and vegetable fibers, hygienic care and anal dilator according to the traditional standardized scheme. The two experimental groups will be subjected to the same standard therapeutic scheme (diet rich in water and vegetable fibers, hygienic) of the controls, in addition to which will be added to oral supplements (group "ProtFlav") and local application as an anal cream (group "ProtCent"). Of the patients in the interventional groups, half will take flavonoid-based supplements (ProtFlav) and the other half will take supplements and anal cream based on Centella asiatica (ProtCent), as better specified below. All patients will be followed for a period of 8 weeks or otherwise until recovery (disappearance of irritation and stop bleeding).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 85 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female affected by acute haemorrhoidal disease
- •Collaborating patients, able to understand
排除标准
- •Women who are pregnant or have been breastfeeding;
- •Previous colorectal surgery;
- •Anal stenosis;
- •Treatment (topical or systemic) with decongestants, diuretics, steroidal anti-inflammatory drugs or NSAIDs, antipyretics, antibiotics or antivirals for other reasons;
- •Psychiatric and / or toxic employees;
- •Age in completed years, less than 18 and over 85;
- •If the patient's personal clinical record does not have at least two controls, it is excluded from the clinical study;
- •Refusal to participate in the study.
研究组 & 干预措施
Standard
standard of care (diet rich in water and vegetable fibers, hygienic)
干预措施: standard of care (Behavioral)
ProtFlav
oral supplements (flavonoid-based supplements - ProtFlav) will be added to standard of care
干预措施: flavonoid-based supplements (Drug)
ProtCent
anal application of a Centella based cream (Centella asiatica - ProtCent) will be added to standard of care
干预措施: Centella Complex (Drug)
结局指标
主要结局
delta of time necessary for the disappearance of bleeding
时间窗: 3 months
comparative assessment of the time necessary for the disappearance of bleeding
次要结局
- delta of BMI (Body Mass Index).(3 months)
- delta of Visual Analog Scale for Pain (VAS Pain)(3 months)
研究者
Massimo Chiaretti
Clinical Professor
University of Roma La Sapienza
